Remission rate and remission predictors of Graves disease in children and adolescents
![]() |
Lee, Sun Hee
(Department of Pediatrics, College of Medicine, Seoul National University)
Lee, Seong Yong (Department of Pediatrics, Seoul National University Boramae Hospital) Chung, Hye Rim (Department of Pediatrics, Seoul National University Bundang Hospital) Kim, Jae Hyun (Department of Pediatrics, College of Medicine, Seoul National University) Kim, Ji Hyun (Department of Pediatrics, College of Medicine, Seoul National University) Lee, Young Ah (Department of Pediatrics, College of Medicine, Seoul National University) Yang, Sei Won (Department of Pediatrics, College of Medicine, Seoul National University) Shin, Choong Ho (Department of Pediatrics, College of Medicine, Seoul National University) |
1 | Glaser NS, Styne DM. Predictors of early remission of hyperthyroidism in children. J Clin Endocrinol Metab 1997;82: 1719-26 DOI ScienceOn |
2 | Hamburger JI. Management of hyperthyroidism in children and adolescents. J Clin Endocrinol Metab 1985;60:1019-24 DOI |
3 | Hamburger JI. Management of hyperthyroidism in children and adolescents. J Clin Endocrinol Metab 1985;60:1019-24 DOI |
4 | Kim H. Management of childhood hyperthyroidism. J Korean Soc Pediatr Endocrinol 1999;4:10-3 |
5 | Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, et al. Clinical features of patients with Graves disease undergoing remission after antithyroid drug treatment. Thyroid 1997;7: 369-75 DOI |
6 | Lippe BM, Landaw EM, Kaplan SA. Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years. J Clin Endocrinol Metab 1987;64:1241-5 DOI |
7 | Perez C, Scrimshaw NS, Munoz JA. Technique of endemic goitre surveys. Monogr Ser World Health Organ 1960;44: 369-83 PUBMED ScienceOn |
8 | Cooper DS. Antithyroid drugs. N Engl J Med 2005;352:905- 17 DOI PUBMED ScienceOn |
9 | Lee JA, Grumbach MM, Clark OH. The optimal treatment for pediatric Graves disease is surgery. J Clin Endocrinol Metab 2007;92:801-3 DOI |
10 | Zimmerman D, Lteif AN. Thyrotoxicosis in children. Endocrinol Metab Clin North Am 1998;27:109-26 DOI ScienceOn |
11 | Quadbeck B, Hoermann R, Roggenbuck U, Hahn S, Mann K, Janssen OE. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves disease. Thyroid 2005;15:1047-54 DOI ScienceOn |
12 | Maugendre D, Massart C. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves disease. Comparison with thyroid stimulating antibody bioassay. Clin Endocrinol (Oxf) 2001;54:89-96 DOI ScienceOn |
13 | Teng CS, Yeung RT. Changes in thyroid-stimulating antibody activity in Graves disease treated with antithyroid drug and its relationship to relapse: a prospective study. J Clin Endocrinol Metab 1980;50:144-7 DOI |
14 | McGregor AM, Petersen MM, Capiferri R, Evered DC, Smith BR, Hall R. Effects of radioiodine on thyrotrophin binding inhibiting immunoglobulins in Graves disease. Clin Endocrinol (Oxf) 1979;11:437-44 DOI |
15 | Lazar L, Kalter-Leibovici O, Pertzelan A, Weintrob N, Josefsberg Z, Phillip M. Thyrotoxicosis in prepubertal children compared with pubertal and postpubertal patients. J Clin Endocrinol Metab 2000;85:3678-82 DOI ScienceOn |
16 | Shim K. Predicted factors of remission in Graves disease. J Korean Soc Pediatr Endocrinol 2007;12:1-5 |
17 | Michelangeli V, Poon C, Taft J, Newnham H, Topliss D, Colman P. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves disease with antithyroid drugs. Thyroid 1998;8:119-24 DOI ScienceOn |
18 | Fisher DA, Grueters A. Thyroid disorders in childhood and adolescence. In Sperling MA, editor. Pediatric Endocrinology. 3rd ed. Philadelphia : WB Saunders Co, 2008:227-53 |
19 | Maugendre D, Gatel A, Campion L, Massart C, Guilhem I, Lorcy Y, et al. Antithyroid drugs and Graves disease--prospective randomized assessment of long-term treatment. Clin Endocrinol (Oxf) 1999;50:127-32 DOI ScienceOn |
20 | Wing SS, Fantus IG. Adverse immunologic effects of antithyroid drugs. CMAJ 1987;136:121-7 ScienceOn |
21 | Kim SY, Yu JS, Shin CH, Yang SW. The outcome of hyperthyroidism with methimazole therapy in childhood. J Korean Soc Pediatr Endocrinol 1996;1:60-8 |
22 | Williams KV, Nayak S, Becker D, Reyes J, Burmeister LA. Fifty years of experience with propylthiouracil-associated hepatotoxicity: what have we learned? J Clin Endocrinol Metab 1997;82:1727-33 DOI ScienceOn |
23 | Cooper DS, Goldminz D, Levin AA, Ladenson PW, Daniels GH, Molitch ME, et al. Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose. Ann Intern Med 1983;98:26-9 PUBMED ScienceOn |
24 | Martino E, Pinchera A, Capiferri R, Macchia E, Sardano G, Bartalena L, et al. Dissociation of responsiveness to thyrotropin-releasing hormone and thyroid suppressibility following antithyroid drug therapy of hyperthyroidism. J Clin Endocrinol Metab 1976;43:543-9 DOI |
25 | Schott M, Morgenthaler NG, Fritzen R, Feldkamp J, Willenberg HS, Scherbaum WA, et al. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves disease. Horm Metab Res 2004;36:92-6 DOI |
26 | Schleusener H, Schwander J, Fischer C, Holle R, Holl G, Badenhoop K, et al. Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves disease. Acta Endocrinol (Copenh) 1989;120:689- 701 PUBMED |
27 | Dahlberg PA, Karlsson FA, Jansson R, Wide L. Thyrotropin- releasing hormone testing during antithyroid drug treatment of Graves disease as an indicator of remission. J Clin Endocrinol Metab 1985;61:1100-4 DOI |
28 | Shulman DI, Muhar I, Jorgensen EV, Diamond FB, Bercu BB, Root AW. Autoimmune hyperthyroidism in prepubertal children and adolescents: comparison of clinical and biochemical features at diagnosis and responses to medical therapy. Thyroid 1997;7:755-60 DOI ScienceOn |
29 | Carella C, Mazziotti G, Sorvillo F, Piscopo M, Cioffi M, Pilla P, et al. Serum thyrotropin receptor antibodies concentrations in patients with Graves disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period. Thyroid 2006; 16:295-302 DOI ScienceOn |
30 | Wilson R, McKillop JH, Henderson N, Pearson DW, Thomson JA. The ability of the serum thyrotrophin receptor antibody (TRAb) index and HLA status to predict long-term remission of thyrotoxicosis following medical therapy for Graves disease. Clin Endocrinol (Oxf) 1986;25:151-6 DOI |
31 | Gorton C, Sadeghi-Nejad A, Senior B. Remission in children with hyperthyroidism treated with propylthiouracil. Long-term results. Am J Dis Child 1987;141:1084-6 DOI |
32 | Zimmermann-Belsing T, Nygaard B, Rasmussen AK, Feldt- Rasmussen U. Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves disease. Eur J Endocrinol 2002;146:173-7 DOI ScienceOn |
33 | Glaser NS, Styne DM. Predicting the likelihood of remission in children with Graves disease: a prospective, multicenter study. Pediatrics 2008;121:e481-8 DOI PUBMED ScienceOn |
34 | Rivkees SA, Dinauer C. An optimal treatment for pediatric Graves disease is radioiodine. J Clin Endocrinol Metab 2007; 92:797-800 DOI ScienceOn |
35 | Benker G, Vitti P, Kahaly G, Raue F, Tegler L, Hirche H, et al. Response to methimazole in Graves disease. The European Multicenter Study Group. Clin Endocrinol (Oxf) 1995;43: 257-63 DOI ScienceOn |
36 | Young ET, Steel NR, Taylor JJ, Stephenson AM, Stratton A, Holcombe M, et al. Prediction of remission after antithyroid drug treatment in Graves disease. Q J Med 1988;66:175-89 PUBMED |
37 | Kim H, Yoon J, Jung M, Suh B, Lee B. Graves disease in prepubertal children compared with pubertal children. J Korean Pediatr Soc 2003;46:76-82 |
38 | Tamai H, Nakagawa T, Fukino O, Ohsako N, Shinzato R, Suematsu H, et al. Thionamide therapy in Graves disease: relation of relapse rate to duration of therapy. Ann Intern Med 1980;92:488-90 DOI PUBMED ScienceOn |
39 | Jaruratanasirikul S, Leethanaporn K, Sriplung H. Thyrotoxicosis in children: treatment and outcome. J Med Assoc Thai 2006;89:967-73 ScienceOn |
![]() |